SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: reconranger, Jesspro, jimbosskow
Search This Board: 
Last Post: 3/25/2017 9:15:24 AM - Followers: 104 - Board type: Free - Posts Today: 4

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#576  Sticky Note To everyone. Please keep your posts talking about jimbosskow 01/30/17 04:31:08 AM
#1819   Lost, nice to see you here again. vidpok45 03/25/17 09:15:24 AM
#1818   just did it, 250,000 patients, thanks. vidpok45 03/25/17 07:41:45 AM
#1817   Good post TC. How many patients are vidpok45 03/25/17 07:37:25 AM
#1816   Goldman's higher revenue estimate is based on trading_cyclist 03/25/17 03:40:20 AM
#1815   Zzaatt, did you read Steve Goldman's article today vidpok45 03/24/17 11:57:59 PM
#1814   I've heard Glick is out until EOM and Lunacy 03/24/17 11:56:36 PM
#1813   Not sure I follow you on this. vidpok45 03/24/17 10:42:13 PM
#1811   I surprised they didn't PR anything about the puravida 03/24/17 10:35:31 PM
#1810   Hah, that's funny. I'm of the opinion zephyroo 03/24/17 09:55:53 PM
#1808   All you can do is talk Vid! The Lost Trader 03/24/17 07:56:57 PM
#1807   I appreciate your taking full responsibility for your vidpok45 03/24/17 07:38:30 PM
#1806   Confirmed on Congress schedule. Presentation at about 6 nferna 03/24/17 07:27:19 PM
#1805   Foxxy, thanks for the welcome. Yes I am zzaatt 03/24/17 06:20:56 PM
#1804   AUPH - i'm hearing 48wk open label trial kei 03/24/17 06:19:55 PM
#1803   After the dilution it settled and then it Foxxycleopatra 03/24/17 06:07:17 PM
#1801   Where do all these idiots come from? Hotrodder1 03/24/17 05:04:50 PM
#1800   Sigh.... ANOTHER BUYING OPPORTUNITY while MM's take out pgh_maulers 03/24/17 03:53:12 PM
#1799   Must be bad news from conference seeing this pgh_maulers 03/24/17 03:52:16 PM
#1795   Give it a month and you alleged longs pgh_maulers 03/24/17 03:09:45 PM
#1791   I don't think he is losing much! He Maciste 03/24/17 02:55:29 PM
#1790   Only way to make money is shorting this pgh_maulers 03/24/17 02:53:01 PM
#1789   Truth hurts.. pgh_maulers 03/24/17 02:46:11 PM
#1786   Lol.. Never trust what these bio's SAY, only what pgh_maulers 03/24/17 02:18:50 PM
#1784   For everyone else on this board, Glickman set Lunacy 03/24/17 02:15:13 PM
#1782   Lol.... Always stop losses being taken out when a pgh_maulers 03/24/17 02:10:57 PM
#1781   Looks like a bunch of stop losses taken Lunacy 03/24/17 01:48:22 PM
#1780   sounds a bit harsh...the deal was done before zephyroo 03/24/17 01:29:50 PM
#1779   Undoubtedly the buyers of the shares are shorting biotech_researcher 03/24/17 01:29:26 PM
#1778   Why are they destroying Aurinia today? biotech_researcher 03/24/17 01:27:58 PM
#1777   Wow... glad I sold out of this dumpster fire. pgh_maulers 03/24/17 01:23:36 PM
#1776   Good SA article discussing potential patient population and Lunacy 03/24/17 11:41:53 AM
#1775   Depending on the effects of the probable defeat vidpok45 03/24/17 09:50:55 AM
#1774   This appears to be setting up to where biotech_researcher 03/24/17 06:53:58 AM
#1773   Inider ILGIN purchased 5,185,185 during the offering. Android 2-73 03/24/17 12:24:40 AM
#1772 Android 2-73 03/24/17 12:17:50 AM
#1771   After the incredible Ariad windfall, I find that biotech_researcher 03/23/17 09:00:29 PM
#1770   We did real good in aria check ctix youssef 03/23/17 02:54:08 PM
#1769   Surely we do need quite a bit yankees7 03/23/17 09:09:45 AM
#1768   AUPH - For me the plan is simple nsomniyak 03/22/17 10:39:09 PM
#1767   What's the plan, folks? Buy Friday, sell nferna 03/22/17 10:28:50 PM
#1766   Hotrodder, why do you have deep conviction that biotech_researcher 03/22/17 09:12:12 PM
#1765   We can't top this Vid, I think. Had Jesspro 03/22/17 05:38:35 PM
#1764   Is that a typo BR? Did you mean short? Hotrodder1 03/22/17 05:30:28 PM
#1763   Open +$9 tomorrow type of carnage!!!!!!! AUPH. stockdawg44 03/22/17 05:17:21 PM
#1762   I'm buying after tomorrow after the carnage is over... biotech_researcher 03/22/17 04:49:26 PM
#1761   yes, yank, we got very lucky at our vidpok45 03/22/17 04:25:54 PM
#1760   I am crossing into retirement soon - this yankees7 03/22/17 03:42:54 PM
#1759   Yes, Jess, you and I will always be vidpok45 03/22/17 03:28:01 PM
#1758   Ariad revisited, lol. Don't worry, this one has Jesspro 03/22/17 03:02:29 PM
#1757   Agreed! Also be a buyer when they pull SvsB 03/22/17 10:09:47 AM